Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations
Clinical trial NCT04790409 · COMPLETED
Trial details
- NCT number
- NCT04790409
- Sponsor
- Zhejiang Cancer Hospital
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-08-01
- Primary completion
- 2023-09-13
- Enrollment
- 21
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.